Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 3,087 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $5.09, for a total value of $15,712.83. Following the transaction, the chief operating officer now owns 109,241 shares of the company’s stock, valued at $556,036.69. The trade was a 2.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Robin Swartz also recently made the following trade(s):

• On Monday, December 23rd, Robin Swartz sold 6,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $5.07 on Friday. Voyager Therapeutics, Inc. has a 52-week low of $4.99 and a 52-week high of $10.66. The stock has a fifty day moving average of $5.91 and a 200 day moving average of $6.72. The firm has a market capitalization of $276.97 million, a price-to-earnings ratio of 7.14 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the company posted ($0.59) EPS. Equities analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on VYGR shares. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price target for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $15.97.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. raised its position in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares in the last quarter. Hunter Perkins Capital Management LLC increased its stake in Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after acquiring an additional 2,025 shares during the last quarter. Empowered Funds LLC raised its position in Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares in the last quarter. Federated Hermes Inc. lifted its stake in Voyager Therapeutics by 0.5% during the second quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after purchasing an additional 2,638 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Voyager Therapeutics by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after purchasing an additional 3,473 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.